We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Doximity (DOCS) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
Doximity (DOCS - Free Report) closed the most recent trading day at $41.36, moving -5.7% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.19%. At the same time, the Dow lost 0.8%, and the tech-heavy Nasdaq lost 0.1%.
Shares of the medical social networking site have depreciated by 1.77% over the course of the past month, underperforming the Medical sector's gain of 0.48%, and the S&P 500's gain of 2.26%.
Analysts and investors alike will be keeping a close eye on the performance of Doximity in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.44, marking a 2.22% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $181.03 million, reflecting a 7.37% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.56 per share and revenue of $645.29 million, indicating changes of +9.86% and +13.13%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Doximity. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.78% higher within the past month. Right now, Doximity possesses a Zacks Rank of #2 (Buy).
Valuation is also important, so investors should note that Doximity has a Forward P/E ratio of 28.04 right now. This denotes a discount relative to the industry average Forward P/E of 29.42.
Meanwhile, DOCS's PEG ratio is currently 1.48. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical Info Systems was holding an average PEG ratio of 2.33 at yesterday's closing price.
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 160, positioning it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow DOCS in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Doximity (DOCS) Declines More Than Market: Some Information for Investors
Doximity (DOCS - Free Report) closed the most recent trading day at $41.36, moving -5.7% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.19%. At the same time, the Dow lost 0.8%, and the tech-heavy Nasdaq lost 0.1%.
Shares of the medical social networking site have depreciated by 1.77% over the course of the past month, underperforming the Medical sector's gain of 0.48%, and the S&P 500's gain of 2.26%.
Analysts and investors alike will be keeping a close eye on the performance of Doximity in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.44, marking a 2.22% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $181.03 million, reflecting a 7.37% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.56 per share and revenue of $645.29 million, indicating changes of +9.86% and +13.13%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Doximity. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.78% higher within the past month. Right now, Doximity possesses a Zacks Rank of #2 (Buy).
Valuation is also important, so investors should note that Doximity has a Forward P/E ratio of 28.04 right now. This denotes a discount relative to the industry average Forward P/E of 29.42.
Meanwhile, DOCS's PEG ratio is currently 1.48. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical Info Systems was holding an average PEG ratio of 2.33 at yesterday's closing price.
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 160, positioning it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow DOCS in the coming trading sessions, be sure to utilize Zacks.com.